Analysis

Pharma Technology Focus – Issue 60

Pharma Technology Focus – Issue 60

Could a temperature-resistant vaccine spell the end for rabies and yellow fever?

Could a temperature-resistant vaccine spell the end for rabies and yellow fever?

Crowdfunding for cancer therapy

Crowdfunding for cancer therapy

Alzheimer’s drugs: will 2017 bring better news?

Alzheimer’s drugs: will 2017 bring better news?

Illuminating drug discovery by mapping all known drugs

Illuminating drug discovery by mapping all known drugs

How an Alzheimer’s drug turned tooth regenerator could unlock regenerative medicine

How an Alzheimer’s drug turned tooth regenerator could unlock regenerative medicine

Nigeria’s HIV ‘breakthrough’: separating truth from hope

Nigeria’s HIV ‘breakthrough’: separating truth from hope

A peptide to prevent pre-diabetes

A peptide to prevent pre-diabetes

Pharma Technology Focus – Issue 56

Pharma Technology Focus – Issue 56

Why the UK NHS needs clinical research

Why the UK NHS needs clinical research

After the cure: addressing side effects in childhood cancer patients

After the cure: addressing side effects in childhood cancer patients

Pharma Technology Focus – Issue 54

Pharma Technology Focus – Issue 54

Debating the value of targeted lung cancer treatments

Debating the value of targeted lung cancer treatments

Genomic array could unlock war against diseases in Africa

Genomic array could unlock war against diseases in Africa

Ketamine: taking aim at depression

Ketamine: taking aim at depression

Antibiotic resistance: the race for the prize

Antibiotic resistance: the race for the prize

Developing new drugs for Tourette syndrome

Developing new drugs for Tourette syndrome

Plague, Flu and Zika: could 2017 bring vaccines for all three?

Plague, Flu and Zika: could 2017 bring vaccines for all three?

Pharma Technology Focus – Issue 51

Pharma Technology Focus – Issue 51

August's top stories: Pfizer-AstraZeneca $1.5bn deal, Cinven buys Bioclinica for $1.4bn

August's top stories: Pfizer-AstraZeneca $1.5bn deal, Cinven buys Bioclinica for $1.4bn

How rebuilding entire immune systems could be the key to curing MS

How rebuilding entire immune systems could be the key to curing MS